Stockwatch: An orphan drug too far
This article was originally published in Scrip
Often when a company releases an announcement that results in its share price going down, and then it keeps going down, the cause for the sell-off is reasonably obvious. Not so for Synageva BioPharma last week. Its positive Phase III trial announcement in the treatment of lysosomal acid lipase (LAL) deficiency was accompanied by a 14% share price drop before the markets closed for the fourth of July weekend (scripintelligence.com, 02 July 2014).
You may also be interested in...
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.
It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.